SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

12 Months Ended

Dec. 31, 2020

SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

SUPPLEMENTARY FINANCIAL DATA

(UNAUDITED)

(In thousands, except per share data)

The following table presents certain unaudited consolidated quarterly financial information for the eight quarters in the periods ended December 31, 2020 and 2019. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein.

	For the Quarter Ended
	March 31,		June 30,		September 30,		December 31,
2020
Total revenue	$	19,862	$	15,008	$	18,257	$	18,730
Costs and expenses		92,338		87,184		94,872		95,220
Loss from operations		(72,476)		(72,176)		(76,615)		(76,490)
Net loss		(83,053)		(62,887)		(73,643)		(58,434)
Basic and diluted net loss per share	$	(1.40)	$	(1.00)	$	(1.16)	$	(0.92)
2019
Total revenue	$	5,338	$	26,150	$	12,427	$	29,499
Costs and expenses		79,004		68,626		77,628		100,071
Loss from operations		(73,666)		(42,476)		(65,201)		(70,572)
Net loss		(72,580)		(39,838)		(58,431)		(65,606)
Basic and diluted net loss per share	$	(1.32)	$	(0.72)	$	(1.05)	$	(1.17)
Share of Total YUPELRI Net Sales (1)
	For the Quarter Ended
	March 31,		June 30,		September 30,		December 31,
2020	$	12,880	$	10,589	$	12,960	$	13,550
2019	$	1	$	3,184	$	5,763	$	10,352

(1) The Company co-promotes YUPELRI in the US under a profit and loss sharing arrangement with Viatris (65% to Viatris; 35% to Theravance Biopharma). The amounts represent the Company’s implied 35% share of the total net sales of YUPELRI that were recognized within Viatris’ financial statements for the periods presented.